Related Experiment Video
Updated: Apr 13, 2026

In Silico Clinical Trials for Cardiovascular Disease
Published on: May 27, 2022
Genotype-based clinical trials in cardiovascular disease
Naveen L Pereira1, Daniel J Sargent2, Michael E Farkouh3
1Division of Cardiovascular Diseases, Department of Internal Medicine, 200 First Street SW, Rochester, MN 55905, USA.
Abstract:
Consensus practice guidelines and the implementation of clinical therapeutic advances are usually based on the results of large, randomized clinical trials (RCTs). However, RCTs generally inform us on an average treatment effect for a presumably homogeneous population, but therapeutic interventions rarely benefit the entire population targeted. Indeed, multiple RCTs have demonstrated that interindividual variability exists both in drug response and in the development of adverse effects. The field of pharmacogenomics promises to deliver the right drug to the right patient. Substantial progress has been made in this field, with advances in technology, statistical and computational methods, and the use of cell and animal model systems. However, clinical implementation of pharmacogenetic principles has been difficult because RCTs demonstrating benefit are lacking. For patients, the potential benefits of performing such trials include the individualization of therapy to maximize efficacy and minimize adverse effects. These trials would also enable investigators to reduce sample size and hence contain costs for trial sponsors. Multiple ethical, legal, and practical issues need to be considered for the conduct of genotype-based RCTs. Whether pre-emptive genotyping embedded in electronic health records will preclude the need for performing genotype-based RCTs remains to be seen.
Insights
Pharmacogenomics aims to personalize medicine by matching drugs to patients, but clinical use is hindered by a lack of genotype-based randomized clinical trials (RCTs). Overcoming ethical and practical hurdles is key for implementing these trials.
Area of Science:
- Pharmacogenomics and personalized medicine
- Clinical trial design
- Genetics and drug response
Background:
- Randomized clinical trials (RCTs) typically assess average treatment effects in homogeneous populations.
- Interindividual variability in drug response and adverse effects is well-documented.
- Pharmacogenomics offers potential for tailored therapies but faces implementation challenges.
Purpose of the Study:
- To explore the need for and challenges of genotype-based RCTs in pharmacogenomics.
- To highlight the potential benefits of personalized medicine through pharmacogenetics.
- To discuss ethical, legal, and practical considerations for genotype-based clinical trials.
Main Methods:
- Review of existing literature on RCTs, pharmacogenomics, and clinical implementation.
- Discussion of technological, statistical, and modeling advances in pharmacogenomics.
- Analysis of ethical, legal, and practical issues related to genotype-based RCTs.
Main Results:
- RCTs provide average treatment effects, not accounting for individual variability in drug response.
- Pharmacogenomics has advanced significantly, but clinical application is limited by a lack of benefit-demonstrating RCTs.
- Genotype-based RCTs could individualize therapy, maximize efficacy, minimize adverse effects, and potentially reduce trial costs.
Conclusions:
- Genotype-based RCTs are crucial for the clinical implementation of pharmacogenetic principles.
- Addressing ethical, legal, and practical challenges is essential for conducting these trials.
- The role of pre-emptive genotyping in electronic health records versus dedicated RCTs requires further investigation.
Related Concept Videos
Clinical Trials: Overview
Pharmacogenomics: Identification of New Drug Targets
Clinical Trials
There are four phases in a clinical trial. A phase one...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Principles of Pharmacogenetics: Types of Genetic Variants
Cardiovascular Drugs: Classification based on Therapeutic Indications

